Health-related quality of life aspects in patients with low-grade glioma

  • M. Klein
Part of the Advances and Technical Standards in Neurosurgery book series (NEUROSURGERY, volume 35)


Standard therapeutic options for brain tumors include surgery, radiotherapy, and chemotherapy. Unfortunately, these same therapies pose risks of neurotoxicity, the most common long-term complications being radiation necrosis, chemotherapy-associated leukoencephalopathy, and cognitive deficits. Currently, there is no consensus on the treatment strategy for these tumors. Because of the relatively slow growth rate of low-grade gliomas, patients have a relatively long expected survival.

Compared to traditional outcome measures like (progression-free) survival, evaluation of health-related quality of life may be time-consuming and burdensome for both the patient and the doctor. Besides, given the relatively low incidence of brain tumors and the ultimately fatal outcome of the disease, the interest in HRQOL emerged relatively late in these patients. Moreover, the notion that the disease itself may affect the patient’s ability to judge his or her own functioning may hinder the use of patient self-reported measures.

In future trials, more sensitive measures of long-term cognitive, functional, and HRQOL outcomes on LGG patients at important time points over the disease trajectory are needed to better understand the changing needs that take place over time.


Health-related quality of life cognitive functioning neurosurgery radiotherapy chemotherapy mood 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aaronson NK, Bakker W, Stewart AL, van Dam FSAM, van Zandwijk N, Yarnold JR, et al. (1987) Multi-dimensional approach to the measurement of quality of life in lung cancer clinical trials. In: Aaronson NK, Beckmann J (eds) The quality of life of cancer patients. Raven Press, New YorkGoogle Scholar
  2. 2.
    Aaronson NK, Cull A, Kaasa S, Spangers M (1985) The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Mental Health 23(2): 75–106Google Scholar
  3. 3.
    Aaronson NK, Muller MJ, Klein M, Heimans JJ, Van der Ploeg HM, Postma TJ, et al. (2008) Compromised health-related quality of life among long-term survivors of low-grade glioma. (submitted)Google Scholar
  4. 4.
    Anderson SI, Taylor R, Whittle IR (1999) Mood disorders in patients after treatment for primary intracranial tumours. Br J Neurosurg 13(5): 480–85PubMedGoogle Scholar
  5. 5.
    Anderson SW, Damasio H, Tranel D (1990) Neuropsychological impairments associated with lesions caused by tumor or stroke. Arch Neurol 47(4): 397–405PubMedGoogle Scholar
  6. 6.
    Andrewes DG, Kaye A, Murphy M, Harris B, Aitken S, Parr C, et al. (2003) Emotional and social dysfunction in patients following surgical treatment for brain tumour. J Clin Neurosci 10(4): 428–33CrossRefPubMedGoogle Scholar
  7. 7.
    Arlt W, Hove U, Muller B, Reincke M, Berweiler U, Schwab F, et al. (1997) Frequent and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. Neurology 49(2): 498–506PubMedGoogle Scholar
  8. 8.
    Béhin A, Delattre JY (2003) Neurologic sequelae of radiotherapy of the nervous system. In: Schiff D, Wen PY (eds) Cancer neurology in clinical practice. Humana Press, Totowa, pp 173–92Google Scholar
  9. 9.
    Bergner M, Bobbitt RA, Carter WB, Gilson BS (1981) The sickness impact profile: development and final revision of a health status measure. Med Care 19(8): 787–805CrossRefPubMedGoogle Scholar
  10. 10.
    Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14(12): 1715–21CrossRefPubMedGoogle Scholar
  11. 11.
    Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP, et al. (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21(13): 2519–24CrossRefPubMedGoogle Scholar
  12. 12.
    Cairncross JG, Laperriere NJ (1989) Low-grade glioma. To treat or not to treat? Arch Neurol 46(11): 1238–39PubMedGoogle Scholar
  13. 13.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19): 1473–79CrossRefPubMedGoogle Scholar
  14. 14.
    Calman KC (1984) Quality of life in cancer patients — an hypothesis. J Med Ethics 10(3): 124–27CrossRefPubMedGoogle Scholar
  15. 15.
    Cella DF, Tulsky DS (1990) Measuring quality of life today: methodological aspects. Oncology (Williston Park) 4(5): 29–38; discussion 69Google Scholar
  16. 16.
    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3): 570–79PubMedGoogle Scholar
  17. 17.
    Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al. (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317(24): 1490–95PubMedGoogle Scholar
  18. 18.
    Costello A, Shallice T, Gullan R, Beaney R (2004) The early effects of radiotherapy on intellectual and cognitive functioning in patients with frontal brain tumours: the use of a new neuropsychological methodology. J Neurooncol 67(3): 351–59CrossRefPubMedGoogle Scholar
  19. 19.
    Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627–42PubMedGoogle Scholar
  20. 20.
    Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M (1996) What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer 74: 1674–79PubMedGoogle Scholar
  21. 21.
    Derogatis LR, Lopez MC (1983) The psychosocial adjustment to illness scale: administration, scoring and procedures manual-I. Clinical Psychometric Research, BaltimoreGoogle Scholar
  22. 22.
    Dimond S (1980) Neuropsychology: a textbook of systems and psychological functions of the human brain. Butterworth, LondonGoogle Scholar
  23. 23.
    Drane LD, Meador KJ (2002) Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 3(5S): 49–53CrossRefPubMedGoogle Scholar
  24. 24.
    Duffau H, Capelle L, Denvil D, Sichez N, Gatignol P, Lopes M, et al. (2003) Functional recovery after surgical resection of low-grade gliomas in eloquent brain: hypothesis of brain compensation. J Neurol Neurosurg Psychiatry 74(7): 901–07CrossRefPubMedGoogle Scholar
  25. 25.
    Duffau H, Capelle L, Denvil D, Sichez N, Gatignol P, Taillandier L, et al. (2003) Usefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions: functional results in a consecutive series of 103 patients. J Neurosurg 98(4): 764–78CrossRefPubMedGoogle Scholar
  26. 26.
    Falleti MG, Maruff P, Burman P, Harris A (2006) The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 31(6): 681–91CrossRefPubMedGoogle Scholar
  27. 27.
    Ferrans CE (1990) Development of a quality of life index for patients with cancer. Oncol Nurs Forum 17 (3 Suppl): 15–19; discussion 20–11PubMedGoogle Scholar
  28. 28.
    Ferrell BR, Hassey Dow K (1997) Quality of life among long-term cancer survivors. Oncology (Williston Park) 11(4): 565–68Google Scholar
  29. 29.
    Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4(12): 1772–79PubMedGoogle Scholar
  30. 30.
    Giovagnoli AR, Tamburini M, Boiardi A (1996) Quality of life in brain tumor patients. J Neurooncol 30(1): 71–80CrossRefPubMedGoogle Scholar
  31. 31.
    Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7(1): 36–44PubMedGoogle Scholar
  32. 32.
    Grassi L, Indelli M, Marzola M, Maestri A, Santini A, Piva E, et al. (1996) Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage 12(5): 300–07CrossRefPubMedGoogle Scholar
  33. 33.
    Gustafsson M, Edvardsson T, Ahlstrom G (2006) The relationship between function, quality of life and coping in patients with low-grade gliomas. Support Care Cancer 14(12): 1205–12CrossRefPubMedGoogle Scholar
  34. 34.
    Guthrie BL, Laws ER Jr (1990) Supratentorial low-grade gliomas. Neurosurg Clin North Am 1(1): 37–48Google Scholar
  35. 35.
    Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC (2003) Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55(4): 992–99PubMedGoogle Scholar
  36. 36.
    Hall RC, Popkin MK, Stickney SK, Gardner ER (1979) Presentation of the steroid psychoses. J Nerv Ment Dis 167(4): 229–36PubMedCrossRefGoogle Scholar
  37. 37.
    Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Selker RG, Fine HA, et al. (2003) Laterality of brain tumors. Neuroepidemiology 22(2): 130–38CrossRefGoogle Scholar
  38. 38.
    Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, et al. (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21): 1831–36CrossRefPubMedGoogle Scholar
  39. 39.
    Karnofsky DA, Abelmann WH, Craver LF (1948) The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634–56CrossRefGoogle Scholar
  40. 40.
    Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205Google Scholar
  41. 41.
    Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT (1996) The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 47(6): 1396–402PubMedGoogle Scholar
  42. 42.
    Keime-Guibert F, Napolitano M, Delattre JY (1998) Neurological complications of radiotherapy and chemotherapy. J Neurol 245: 695–708CrossRefPubMedGoogle Scholar
  43. 43.
    Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, et al. (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 34(12): 1902–09CrossRefPubMedGoogle Scholar
  44. 44.
    Klein M, Engelberts NHJ, Van der Ploeg HM, Kasteleijn-Nolst Trenité DGA, Aaronson NK, Taphoorn MJB, et al. (2003) Epilepsy in low-grade gliomas: the impact on cognitive functioning and quality of life. Ann Neurol 54(4): 514–20CrossRefPubMedGoogle Scholar
  45. 45.
    Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360(9343): 1361–68CrossRefPubMedGoogle Scholar
  46. 46.
    Kornblith AB, Holland JC (1996) Model for quality-of-life research from the Cancer and Leukemia Group B: the telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst Monogr (20): 55–62PubMedGoogle Scholar
  47. 47.
    Laack NN, Brown PD, Ivnik RJ, Furth AF, Ballman KV, Hammack JE, et al. (2005) Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63(4): 1175–83PubMedGoogle Scholar
  48. 48.
    Lazarus RS, Folkman S (1984) Stress, appraisal and coping. Springer, Berlin, Heidelberg, New YorkGoogle Scholar
  49. 49.
    Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, et al. (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14(4): 391–98CrossRefPubMedGoogle Scholar
  50. 50.
    Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, et al. (2004) Longterm outcome of oligodendrogliomas. Neurology 62(10): 1783–87PubMedGoogle Scholar
  51. 51.
    Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, et al. (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15(4): 1294–301PubMedGoogle Scholar
  52. 52.
    Lilja A, Hagstadius S, Risberg J, Salford LG, Smith GJW, Ohman R (1992) Frontal lobe dynamics in brain tumor patients: a study of regional blood flow and affective changes before and after surgery. Neuropsychiatry Neuropsychol Behav Neurol 5: 294–300Google Scholar
  53. 53.
    Lopes MB, Laws ER Jr (2002) Low-grade central nervous system tumors. Neurosurg Focus 12(2): E1CrossRefGoogle Scholar
  54. 54.
    Mackworth N, Fobair P, Prados MD (1992) Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol 14(3): 243–53CrossRefPubMedGoogle Scholar
  55. 55.
    Mainio A, Tuunanen S, Hakko H, Niemela A, Koivukangas J, Rasanen P (2006) Decreased quality of life and depression as predictors for shorter survival among patients with lowgrade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci 256(8): 516–21CrossRefPubMedGoogle Scholar
  56. 56.
    Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, et al. (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53(4): 524–28CrossRefPubMedGoogle Scholar
  57. 57.
    Mason WP, Krol GS, De Angelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1): 203–07PubMedGoogle Scholar
  58. 58.
    Meador KJ (2006) Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res 68(1): 63–67CrossRefPubMedGoogle Scholar
  59. 59.
    Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME, et al. (2007) Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology 69(22): 2076–84CrossRefPubMedGoogle Scholar
  60. 60.
    Meyers CA, Berman SA, Scheibel RS, Hayman A (1992) Case report: acquired antisocial personality disorder associated with unilateral left orbital frontal lobe damage. J Psychiatry Neurosci 17(3): 121–25PubMedGoogle Scholar
  61. 61.
    Olson JD, Riedel E, De Angelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7): 1442–48PubMedGoogle Scholar
  62. 62.
    Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, et al. (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14(12): 1722–26CrossRefPubMedGoogle Scholar
  63. 63.
    Packer RJ, Mehta M (2002) Neurocognitive sequelae of cancer treatment. Neurology 59(1): 8–10PubMedGoogle Scholar
  64. 64.
    Pahlson A, Ek L, Ahlstrom G, Smits A (2003) Pitfalls in the assessment of disability in individuals with low-grade gliomas. J Neurooncol 65(2): 149–58CrossRefPubMedGoogle Scholar
  65. 65.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20(8): 2076–84CrossRefPubMedGoogle Scholar
  66. 66.
    Popper KR, Eccles JC (1977) The self and its brain. Springer, Berlin, HeidelbergGoogle Scholar
  67. 67.
    Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low-grade gliomas. J Neurooncol 82(3): 281–88CrossRefPubMedGoogle Scholar
  68. 68.
    Pringle AM, Taylor R, Whittle IR (1999) Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 13(1): 46–51CrossRefPubMedGoogle Scholar
  69. 69.
    Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31: 431–36CrossRefPubMedGoogle Scholar
  70. 70.
    Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJB (2001) Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 56(5): 618–23PubMedGoogle Scholar
  71. 71.
    Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, et al. (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61(5): 484–90CrossRefPubMedGoogle Scholar
  72. 72.
    Sachsenheimer W, Piotrowski W, Bimmler T (1992) Quality of life in patients with intracranial tumors on the basis of Karnofsky’s performance status. J Neurooncol 13(2): 177–81CrossRefPubMedGoogle Scholar
  73. 73.
    Salo J, Niemela A, Joukamaa M, Koivukangas J (2002) Effect of brain tumour laterality on patients’ perceived quality of life. J Neurol Neurosurg Psychiatry 72(3): 373–77CrossRefPubMedGoogle Scholar
  74. 74.
    Schag CA, Ganz PA, Heinrich RL (1991) Cancer Rehabilitation Evaluation System-Short Form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer 68(6): 1406–13CrossRefPubMedGoogle Scholar
  75. 75.
    Scheibel RS, Meyers CA, Levin VA (1996) Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 30(1): 61–69CrossRefPubMedGoogle Scholar
  76. 76.
    Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 2(5): 472–83PubMedGoogle Scholar
  77. 77.
    Sintonen H (2001) The 15D instrument of health-related quality of life: properties and applications. Ann Med 33(5): 328–36CrossRefPubMedGoogle Scholar
  78. 78.
    Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57(1): 109–12PubMedGoogle Scholar
  79. 79.
    Spielberger C, Gorsuch R, Lushene R (1970) Manual for the state-trait anxiety inventory. Consulting Psychologist Press, Palo Alto, CaliforniaGoogle Scholar
  80. 80.
    Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34(12): 585–97CrossRefPubMedGoogle Scholar
  81. 81.
    Stewart AL, Hays RD, Ware JE Jr (1988) The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 26(7): 724–35CrossRefPubMedGoogle Scholar
  82. 82.
    Stewart AL, Ware, JE (eds) (1992) Measuring functioning and well-being: the medical outcomes study approach. Duke University Press, Durham, NCGoogle Scholar
  83. 83.
    Struik K, Klein M, Heimans JJ, Gielissen MF, Blijenberg G, Taphoorn MJB, et al. (2009) Fatigue in low-grade glioma. J Neurooncol 27(22): 3712–22Google Scholar
  84. 84.
    Surma-aho O, Niemela M, Vilkki J, Kouri M, Brander A, Salonen O, et al. (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56(10): 1285–90PubMedGoogle Scholar
  85. 85.
    Taphoorn MJB, Heimans JJ, Snoek FJ, Lindeboom J, Oosterink B, Wolbers JG, et al. (1992) Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 55(5): 372–76CrossRefPubMedGoogle Scholar
  86. 86.
    Taphoorn MJB, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurology 3(3): 159–68CrossRefPubMedGoogle Scholar
  87. 87.
    Taphoorn MJB, Schiphorst AK, Snoek FJ, Lindeboom J, Wolbers JG, Karim AB, et al. (1994) Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36(1): 48–54CrossRefPubMedGoogle Scholar
  88. 88.
    Trojanowski T, Peszynski J, Turowski K, Markiewicz P, Goscinski I, Bielawski A, et al. (1989) Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J Neurosurg 70(1): 18–23CrossRefPubMedGoogle Scholar
  89. 89.
    van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurology 6(5): 421–30CrossRefPubMedGoogle Scholar
  90. 90.
    van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C (1998) Supratentorial low-grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64(5): 581–87CrossRefPubMedGoogle Scholar
  91. 91.
    Weitzner MA, Meyers CA, Byrne K (1996) Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg 84(1): 29–34CrossRefPubMedGoogle Scholar
  92. 92.
    Wen PY (2003) Central nervous system complications of cancer therapy. In: Schiff D, Wen PY (eds) Cancer neurology in clinical practice. Humana Press, Totowa, 21531 ppGoogle Scholar
  93. 93.
    Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2(7): 395–403CrossRefPubMedGoogle Scholar
  94. 94.
    Witte OW (1998) Lesion-induced plasticity as a potential mechanism for recovery and rehabilitative training. Curr Opin Neurol 11(6): 655–62CrossRefPubMedGoogle Scholar
  95. 95.
    Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, et al. (2002) Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54(5): 1405–09PubMedGoogle Scholar
  96. 96.
    Zung WW (1965) A self-rating depression scale. Arch Gen Psychiatry 12: 63–70PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2010

Authors and Affiliations

  • M. Klein
    • 1
  1. 1.Department of Medical PsychologyVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations